Ensign Peak Advisors
COGT icon

Ensign Peak Advisors’s Cogent Biosciences COGT Stock Holding History

Ensign Peak Advisors’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.7M Sell
457,302
-115,570
-20% -$4.04M 0.03% 344
2026
Q1 		$22M Buy
572,872
+151,332
+36% +$5.59M 0.04% 291
2025
Q4 		$15M Buy
421,540
+395,915
+1,545% +$11.1M 0.03% 331
2025
Q3 		$368K Sell
25,625
-23,700
-48% -$281K ﹤0.01% 1515
2025
Q2 		$354K Buy
49,325
+30,500
+162% +$169K ﹤0.01% 1633
2025
Q1 		$113K Buy
+18,825
New +$148K ﹤0.01% 1684
2023
Q1 		– Sell
-51,138
Closed -$591K – 1774
2022
Q4 		$591K Hold
51,138
– – ﹤0.01% 1565
2022
Q3 		$763K Hold
51,138
– – ﹤0.01% 1224
2022
Q2 		$461K Buy
+51,138
New +$349K ﹤0.01% 1499

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Ensign Peak Advisors's COGT Position: Q2 2026 in Review

Ensign Peak Advisors reduced its Cogent Biosciences (COGT) stake by 20% in Q2 2026, selling an estimated $4.04M and leaving 457,302 shares worth $17.7M. The position accounts for 0.03% of the portfolio, ranked #344.

Ensign Peak Advisors first reported a position in COGT in Q2 2022 and has held it in 9 quarters since. The position peaked at $22M in Q1 2026. 322 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Ensign Peak Advisors held 457,302 shares of Cogent Biosciences worth $17.7M as of Q2 2026.
  • Ensign Peak Advisors sold 115,570 Cogent Biosciences shares in Q2 2026, an estimated $4.04M.
  • Cogent Biosciences made up 0.03% of Ensign Peak Advisors's portfolio in Q2 2026, its #344 holding.
  • Ensign Peak Advisors first reported a position in Cogent Biosciences in Q2 2022 and has held it in 9 quarters since.
  • Ensign Peak Advisors's Cogent Biosciences position peaked at $22M in Q1 2026.
  • 322 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.